Company intelligence / Profile preview

Canaery

Alachua, Florida, United Statescanaery.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Canaery is developing a neural interface technology that digitizes the sense of smell. The company recently received funding from the US National Science Foundation Convergence Accelerator to create a safe fentanyl substitute for training scent detection animals and validate their nose-computer interface system for detecting fentanyl and smokeless gunpowder in real-world scenarios[3].

Modalities: Neural interfacesAI/machine learning
Industry: Veterinary

Partnerships

US National Science Foundation Convergence Accelerator

Beyond the preview

Go deeper on Canaery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canaery.

Explore the full profile